wet AMD Trials

Opthea has reported encouraging results from a Phase 1/2a study in wet AMD patients and will report outcomes from a 366 patient Phase 2b wet AMD clinical trial in 4Q’19

DME Trials

Opthea is investigating OPT-302 administered in combination with anti-VEGF-A therapy in a Phase 1b/2a study for the treatment of persistent/refractory central-involved diabetic macular edema (DME)

Opthea’s Purpose

Opthea is developing a novel therapeutic, OPT-302 to improve vision and reduce retinal swelling in patients with eye diseases that affect the back-of-the-eye or retina.
This lead therapeutic candidate is currently being investigated in two large Phase 2 clinical trials to determine if OPT-302 improves visual acuity in patients receiving standard of care therapy for wet AMD and DME.  Opthea has made significant advances in the progress of these studies over the past 12 months and anticipates reporting outcomes from these trials by the end of calendar year 2019.
Wet (neovascular) age-related macular degeneration (wet AMD) and diabetic macular edema (DME) are the leading causes of visual impairment in the elderly and diabetic populations respectively.  Globally, progressive vision loss associated with wet AMD and DME contributes to significant healthcare and economic costs and greatly impacts patient independence and quality of life.  Current treatment options for wet AMD and DME patients are limited and work sub-optimally in the majority of patients.
With the prevalence of both diseases on the rise given the aging population and rising incidence of diabetes worldwide, there remains a significant market opportunity for novel therapies that can improve vision in patients with these diseases.